Overview

Data as of April 06, 2020 02:04 pm EDT

Press Releases

Summary Toggle Madrigal Pharmaceuticals Reports 2019 Fourth Quarter and Full Year Financial Results and Highlights

February 26, 2020

CONSHOHOCKEN, Pa. , Feb. 26, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its fourth quarter and full year 2019 financial results and highlights: “Madrigal made significant progress during 2019 in executing our business strategy and advancing the development
Summary Toggle Madrigal Pharmaceuticals Announces First Patient Dosed in MAESTRO-NAFLD-1, a Second Phase 3 Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Resmetirom (MGL-3196) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Presumed NASH (

December 18, 2019

-- MAESTRO-NAFLD-1 is the second resmetirom Phase 3 clinical trial in patients with NASH and presumed NASH and follows MAESTRO-NASH, a Phase 3 multi-center, double-blind, randomized, placebo-controlled study in patients with non-alcoholic steatohepatitis ( NASH ) and fibrosis, that was initiated in
Summary Toggle Madrigal Pharmaceuticals Announces Pricing of Secondary Offering

December 10, 2019

WEST CONSHOHOCKEN, Pa. , Dec. 10, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal” or the “Company”), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the treatment of

Filing date	Form	Description	Filing Group	View
June 13, 2005	RW	Withdrawal of registration statement filed under the Securities Act	Other	0001047469-05-017134.rtf 0001047469-05-017134.xls 0001047469-05-017134.pdf
February 13, 2007	4	Statement of changes in beneficial ownership of securities	3,4,5	0001179110-07-003589.rtf 0001179110-07-003589.pdf
February 13, 2007	4	Statement of changes in beneficial ownership of securities	3,4,5	0001179110-07-003591.rtf 0001179110-07-003591.pdf